Rising Teen Marijuana Abuse Outpaces Alcohol Decline: Study

Dec.05.2022
Rising Teen Marijuana Abuse Outpaces Alcohol Decline: Study
Marijuana abuse among US youths has increased by 245% since 2000, while alcohol abuse has steadily declined.

Since 2000, there has been a 245% increase in marijuana abuse among American teenagers, while alcohol abuse has steadily declined during the same period.


According to a nationally peer-reviewed study, intentional abuse and misuse reported to the National Poison Data System (NPDS) were tracked through the year 2020.


The investigation results published today in the peer-reviewed journal "Clinical Toxicology" have found that there were over 338,000 incidents of intentional abuse or misuse in American children aged 6 to 18 years old.


Most of the cases occurred in males (58.3%), with over 80% of all reported cases of exposure occurring in young individuals aged between 13 and 18. Overall, more than 32% of instances resulted in clinical outcomes worse than minor.


A new report has revealed changes in patterns over time. For instance, during the research period, Ritalin was the substance with the most reported use, but it peaked in 2006 and has since declined.


Furthermore, the year 2000 had the highest number of abuse cases involving contact with ethanol, but since then, incidents of children drinking alcohol have steadily declined over the years.


In contrast, cases of marijuana exposure remained relatively stable from the year 2000 to 2009 and then began to steadily increase from 2011 onwards, with an even greater increase in cases observed from the years 2017 to 2020.


Experts analyzing data attribute the increase in marijuana use to the growing popularity of edible marijuana products, which are now widely used throughout the country.


According to Dr. Adrienne Hughes, an assistant professor of emergency medicine at Oregon Health & Science University and one of the authors of the study, from 2000 to 2013, the number of cases of ethanol abuse exceeded the number of cases involving marijuana each year.


However, by 2014, this trend had reversed.


Since 2014, cases of exposure to marijuana have exceeded cases of exposure to alcohol every year, and the numbers have been increasing each year," said Hughes.


Though all rates of marijuana abuse are on the rise, the average monthly growth rate of marijuana consumption is the highest when compared with all other forms. This indicates that teenagers have shifted from smoking marijuana to other methods of consumption. Marijuana extracts, such as those used in marijuana electronic cigarette products, are also increasingly popular.


Hughes said, "These edible and electronic vaping products are typically marketed in a way that appeals to young people and are considered more independent and convenient.


Nevertheless, despite being perceived as having minimal harm, studies indicate that this is not necessarily the case.


According to Hughes, "While smoking marijuana typically leads to an immediate high, consuming it in an edible form can take several hours to take effect, which may cause some people to consume more and experience unexpected and unpredictable highs.


Since 2017, there has been a sharp increase in the number of children using marijuana, coinciding with a wave of decriminalization legislation in the United States. As of 2022, marijuana is legal for adult recreational use in 19 states and legal for medical use in 36 states.


Although marijuana is only legal for adults and not for children, the authors of this study argue that it makes it easier for children and adolescents to come into contact with the drug, and leads people to believe that it is safe.


Our research describes the rising trend of adolescent marijuana abuse, particularly those involving edible products," said Hughes.


These survey results highlight continued concern among people about the impact of rapid marijuana legalization on this vulnerable population.


In addition to marijuana, the study also revealed cases of teenage abuse of non-prescription drugs. Between 2001 and 2016, the highest number of drug abuse cases were related to dextromethorphan, a non-prescription cold and cough medication. Oral antihistamines were also among the most commonly abused drugs in this study.


Deaths caused by drug abuse are rare, occurring in only 0.1% of cases among 450 young people. The incidence of death is higher among males and teenagers aged 16-18. Opioids are most commonly associated with these deaths.


Furthermore, although there were 57,488 incidents involving children aged 6 to 12, these cases typically do not involve "traditional" drugs but rather vitamins, plants, melatonin, hand sanitizer, and other items.


The limitations of this study are restricted to exposure cases categorized as abuse or misuse. "It is possible that other cases of misuse or abuse may have been classified in another manner and therefore missed," the authors report.


2FIRSTS will continue to follow and report on this topic. Further updates will be posted on the '2FIRSTS APP'. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Again Meets Religious Authority Over Cigarette Alternatives as Perlis Mufti Responds on Halal Criteria
Philip Morris Malaysia Managing Director Naeem Shahab Khan met Perlis Mufti Mohd Asri Zainul Abidin on September 17 and presented the company's shift from conventional cigarettes toward alternative products. The mufti said a product could be considered halal if it is clean, its side effects are not harmful or can be controlled, and it does not involve excessive waste. His remarks did not mention IQOS or any other specific PMI product and did not amount to a new product-specific religious ruling. It was at least the second publicly reported engagement between Philip Morris Malaysia and a Malaysian religious institution over cigarette alternatives within six months.
Regulations
Sep.18 by 2Firsts Perspectives
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23